<DOC>
	<DOCNO>NCT02397694</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability bictegravir ( BIC ) + emtricitabine/tenofovir alafenamide ( FTC/TAF ) fix dose combination ( FDC ) versus dolutegravir ( DTG ) + FTC/TAF HIV-1 Infected , antiretroviral treatment-naive adult . This study also evaluate pharmacokinetic ( PK ) profile BIC , FTC TAF .</brief_summary>
	<brief_title>Safety Efficacy Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide HIV-1 Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Key Antiretroviral naive ( ≤ 10 day prior therapy antiretroviral agent ) Plasma HIV1 RNA level ≥ 1,000 copies/mL screen Screening genotype report provide Gilead Sciences must show sensitivity tenofovir ( TFV ) FTC Adequate renal function measure estimate glomerular filtration rate ≥ 70 mL/min accord CockcroftGault formula CD4+ cell count &gt; 200 cells/µL screen Key A new AIDSdefining condition diagnose within 30 day prior screen define study protocol Prior use antiretrovirals set preexposure prophylaxis ( PrEP ) post exposure prophylaxis ( PEP ) Chronic hepatitis B virus ( HBV ) infection Hepatitis C infection ( Individuals hepatitis C virus ( HCV ) Ab positive , documented negative HCV RNA , eligible ) Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Participation clinical trial without prior approval sponsor prohibit participate trial Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adult</keyword>
	<keyword>HIV</keyword>
	<keyword>naive</keyword>
</DOC>